Patents by Inventor Douglas R. Kern
Douglas R. Kern has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220009971Abstract: Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV.Type: ApplicationFiled: September 14, 2021Publication date: January 13, 2022Inventors: David B. Weiner, Bernadette Ferraro, Jian Yan, Patricia A. Brown, Rodney A. Bowling, Douglas R. Kern, Mathura P. Ramanathan, Niranjan Y. Sardesai, Karuppiah Muthumani
-
Patent number: 11124545Abstract: Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV.Type: GrantFiled: May 20, 2019Date of Patent: September 21, 2021Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.Inventors: David B. Weiner, Bernadette Ferraro, Jian Yan, Patricia A. Brown, Rodney A. Bowling, Douglas R. Kern, Mathura P. Ramanathan, Niranjan Y. Sardesai, Karuppiah Muthumani
-
Publication number: 20200017553Abstract: Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV.Type: ApplicationFiled: May 20, 2019Publication date: January 16, 2020Inventors: David B. Weiner, Bernadette Ferraro, Jian Yan, Patricia A. Brown, Rodney A. Bowling, Douglas R. Kern, Mathura P. Ramanathan, Niranjan Y. Sardesai, Karuppiah Muthumani
-
Patent number: 10294278Abstract: Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV.Type: GrantFiled: August 3, 2015Date of Patent: May 21, 2019Inventors: David B. Weiner, Bernadette Ferraro, Jian Yan, Patricia A. Brown, Rodney A. Bowling, Douglas R. Kern, Mathura P. Ramanathan, Niranjan Y. Sardesai, Karuppiah Muthumani
-
Publication number: 20160039886Abstract: Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV.Type: ApplicationFiled: August 3, 2015Publication date: February 11, 2016Inventors: David B. Weiner, Bernadette Ferraro, Jian Yan, Patricia A. Brown, Rodney A. Bowling, Douglas R. Kern, Mathura P. Ramanathan, Niranjan Y. Sardesai, Karuppiah Muthumani
-
Patent number: 9109014Abstract: Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV.Type: GrantFiled: November 2, 2010Date of Patent: August 18, 2015Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.Inventors: David B Weiner, Bernadette Ferraro, Jian Yan, Patricia A Brown, Rodney A Bowling, Douglas R Kern, Mathura P Ramanathan, Niranjan Y Sardesai, Karuppiah Muthumani
-
Publication number: 20120282217Abstract: Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV.Type: ApplicationFiled: November 2, 2010Publication date: November 8, 2012Inventors: David B. Weiner, Bernadette Ferraro, Jian Yan, Patricia A. Brown, Rodney A. Bowling, Douglas R. Kern, Mathura P. Ramanathan, Niranjan Y. Sardesai, Karuppiah Muthumani
-
Patent number: 8178504Abstract: The present invention pertains to compositions and methods useful for treating anemia and other effects that are commonly associated in cancer bearing animals. The invention is accomplished by delivering an effective amount of a nucleic acid expression construct that encodes a GHRH or functional biological equivalent thereof into a tissue of an animal and allowing expression of the encoded gene in the animal.Type: GrantFiled: March 21, 2007Date of Patent: May 15, 2012Assignee: VGX Pharmaceuticals, Inc.Inventors: Ruxandra Draghia-Akli, Robert H. Carpenter, Douglas R. Kern, Robert J. Schwartz, Glen King, Kevin Hahn, Malcolm K. Brenner
-
Patent number: 7664545Abstract: The present invention relates to a modular electrode system, and its use, for facilitating the introduction of a macromolecule into cells of a selected tissue in a body or plant. The modular electrode system comprises a non-symmetrically arranged plurality of needle electrodes; a hypodermic needle; an electrical connector that provides a conductive link from a programmable constant-current pulse controller to the plurality of needle electrodes; and a power source. In a preferred embodiment of the present invention, an operator can grasp the plurality of needle electrodes that are mounted on a support structure and firmly insert the them into the selected tissue in a body or plant. The macromolecules are then delivered via the hypodermic needle into the selected tissue. The programmable constant-current pulse controller is activated and constant-current electrical pulse is applied to the plurality of needle electrodes.Type: GrantFiled: July 28, 2006Date of Patent: February 16, 2010Assignee: VGX Pharmaceuticals, Inc.Inventors: Allan Westersten, William R. Wilkinson, Ruxandra Draghia-Akli, Robert H. Carpenter, Douglas R. Kern
-
Publication number: 20090170748Abstract: The present invention pertains to compositions and methods for plasmid-mediated supplementation. The compositions and methods are useful for treating anemia and other effects that are commonly associated in cancer bearing animals. Overall, the embodiments of the invention can be accomplished by delivering an effective amount of a nucleic acid expression construct that encodes a GHRH or functional biological equivalent thereof into a tissue of an animal and allowing expression of the encoded gene in the animal. For example, when such a nucleic acid sequence is delivered into the specific cells of the animal tissue specific constitutive expression is achieved.Type: ApplicationFiled: March 21, 2007Publication date: July 2, 2009Applicants: Advisys, Inc., Baylor College of MedicineInventors: Ruxandra Draghia-Akli, Robert H. Carpenter, Douglas R. Kern, Robert J. Schwartz, Glen King, Kevin Hahn, Malcolm K. Brenner
-
Publication number: 20080194511Abstract: One aspect of the current invention is an optimized synthetic mammalian expression plasmid (e.g. pAV0201). This new plasmid comprise a therapeutic element, and a replication element. The therapeutic element of the new plasmid comprises a eukaryotic promoter; a 5? untranslated region (“UTR”); a codon-optimized-eukaryotic therapeutic gene sequence; and a poly adenylation signal. The therapeutic elements of this plasmid are operatively linked and located in a first operatively-linked arrangement. Additionally, the optimized synthetic mammalian expression plasmid comprises replication elements, wherein the replication elements are operatively linked and located in a second operatively-linked arrangement. The replication elements comprise a selectable marker gene promoter, a ribosomal binding site, and an origin of replication. The first-operatively-linked arrangement and the second-operatively-linked arrangement comprise a circular structure of the codon optimized synthetic mammalian expression plasmid.Type: ApplicationFiled: November 16, 2007Publication date: August 14, 2008Applicant: VGX PHARMACEUTICLAS, INC.Inventors: Ruxandra Draghia-Akli, Ronald V. Abruzzese, Douglas R. Kern
-
Patent number: 7316925Abstract: One aspect of the current invention is an optimized synthetic mammalian expression plasmid (e.g. pAV0201). This new plasmid comprise a therapeutic element, and a replication element. The therapeutic element of the new plasmid comprises a eukaryotic promoter; a 5? untranslated region (“UTR”); a codon-optimized-eukaryotic therapeutic gene sequence; and a poly adenylation signal. The therapeutic elements of this plasmid are operatively linked and located in a first operatively-linked arrangement. Additionally, the optimized synthetic mammalian expression plasmid comprises replication elements, wherein the replication elements are operatively linked and located in a second operatively-linked arrangement. The replication elements comprise a selectable marker gene promoter, a ribosomal binding site, and an origin of replication. The first-operatively-linked arrangement and the second-operatively-linked arrangement comprise a circular structure of the codon optimized synthetic mammalian expression plasmid.Type: GrantFiled: July 15, 2003Date of Patent: January 8, 2008Assignee: VGX Pharmaceuticals, Inc.Inventors: Ruxandra Draghia-Akli, Ronald V. Abruzzese, Douglas R. Kern
-
Patent number: 7245963Abstract: The present invention relates to a modular electrode system, and its use, for facilitating the introduction of a macromolecule into cells of a selected tissue in a body or plant. The modular electrode system comprises a plurality of needle electrodes; a hypodermic needle; an electrical connector that provides a conductive link from a programmable constant-current pulse controller to the plurality of needle electrodes; and a power source. In a preferred embodiment of the present invention, an operator can grasp the plurality of needle electrodes that are mounted on a support structure and firmly insert the them into the selected tissue in a body or plant. The macromolecules are then delivered via the hypodermic needle into the selected tissue. The programmable constant-current pulse controller is activated and constant-current electrical pulse is applied to the plurality of needle electrodes.Type: GrantFiled: March 7, 2002Date of Patent: July 17, 2007Assignee: ADViSYS, Inc.Inventors: Ruxandra Draghia-Akli, Robert H. Carpenter, Douglas R. Kern, Allan Westersten, William R. Wilkinson
-
Patent number: 7241744Abstract: The present invention pertains to compositions and methods for plasmid-mediated supplementation. The compositions and method are useful for retarding the growth of the tumor, and retarding cachexia, wasting, anemia and other effects that are commonly associated in cancer bearing animals. Overall, the embodiments of the invention can be accomplished by delivering an effective amount of a nucleic acid expression construct that encodes a GHRH or functional biological equivalent thereof into a tissue of an animal and allowing expression of the encoded. gene in the animal. For example, when such a nucleic acid sequence is delivered into the specific cells of the tissue specific constitutive expression is achieved.Type: GrantFiled: December 10, 2002Date of Patent: July 10, 2007Assignees: Baylor College of Medicine, ADViSYS, Inc.Inventors: Ruxandra Draghia-Akli, Robert H. Carpenter, Douglas R. Kern, Robert J. Schwartz, Glen King, Kevin Hahn, Malcolm K. Brenner
-
Publication number: 20040167458Abstract: The present invention relates to a modular electrode system, and its use, for facilitating the introduction of a macromolecule into cells of a selected tissue in a body or plant. The modular electrode system comprises a plurality of needle electrodes; a hypodermic needle; an electrical connector that provides a conductive link from a programmable constant-current pulse controller to the plurality of needle electrodes; and a power source. In a preferred embodiment of the present invention, an operator can grasp the plurality of needle electrodes that are mounted on a support structure and firmly insert the them into the selected tissue in a body or plant. The macromolecules are then delivered via the hypodermic needle into the selected tissue. The programmable constant-current pulse controller is activated and constant-current electrical pulse is applied to the plurality of needle electrodes.Type: ApplicationFiled: March 7, 2002Publication date: August 26, 2004Inventors: Ruxandra Draghia-Akli, Robert H. Carpenter, Douglas R. Kern, Allan Westersten, William R. Wilkinson
-
Publication number: 20040092009Abstract: One aspect of the current invention is an optimized synthetic mammalian expression plasmid (e.g. pAV0201). This new plasmid comprise a therapeutic element, and a replication element. The therapeutic element of the new plasmid comprises a eukaryotic promoter; a 5′ untranslated region (“UTR”); a codon-optimized-eukaryotic therapeutic gene sequence; and a poly adenylation signal. The therapeutic elements of this plasmid are operatively linked and located in a first operatively-linked arrangement. Additionally, the optimized synthetic mammalian expression plasmid comprises replication elements, wherein the replication elements are operatively linked and located in a second operatively-linked arrangement. The replication elements comprise a selectable marker gene promoter, a ribosomal binding site, and an origin of replication.Type: ApplicationFiled: July 15, 2003Publication date: May 13, 2004Applicant: ADVISYS, Inc.Inventors: Ruxandra Draghia-Akli, Ronald V. Abruzzese, Douglas R. Kern
-
Publication number: 20040057941Abstract: The present invention pertains to compositions and methods for plasmid-mediated supplementation. The compositions and method are useful for retarding the growth of the tumor, and retarding cachexia, wasting, anemia and other effects that are commonly associated in cancer bearing animals. Overall, the embodiments of the invention can be accomplished by delivering an effective amount of a nucleic acid expression construct that encodes a GHRH or functional biological equivalent thereof into a tissue of an animal and allowing expression of the encoded gene in the animal. For example, when such a nucleic acid sequence is delivered into the specific cells of the animal tissue specific constitutive expression is achieved. Furthermore, external regulation of the GHRH or functional biological equivalent thereof gene can be accomplished by utilizing inducible promoters that are regulated by molecular switch molecules, which are given to the animal.Type: ApplicationFiled: December 10, 2002Publication date: March 25, 2004Applicants: ADViSYS, Inc., Baylor College of MedicineInventors: Ruxandra Draghia-Akli, Robert H. Carpenter, Douglas R. Kern, Robert J. Schwartz, Glen King, Kevin Hahn, Malcolm K. Brenner
-
Publication number: 20040014645Abstract: Plasmid DNA delivered by injection/electroporation to the skeletal muscle can be expressed, and physiologic levels of transgene could be achieved into the circulation. Nevertheless, stabilization of naked DNA may be required and necessary in some cases, as prolonged storage at different temperatures before usage, injection into a large number of animals, etc. It is imperative that the associated compound should not be toxic to the cells (e.g. muscle cells) or cause breakage of plasmid DNA. It would be preferable for the coated DNA to have a similar or increased uptake into the target cells. Low molecular weight poly-L-glutamate compounds have all the desired properties. It was determined that mole/mole ratio DNA/PLG is the optimum concentration for gene therapeutic applications to the skeletal muscle, resulting in increased expression of the transgene, with no damage to the target tissue. Furthermore, stabilization of plasmid DNA by PLG has never been observed or described in the literature.Type: ApplicationFiled: March 24, 2003Publication date: January 22, 2004Applicant: ADVISYS, Inc.Inventors: Ruxandra Draghia-Akli, Robert H. Carpenter, Douglas R. Kern, Leigh Anne Hill, Heather Attra, Henry Hebel
-
Publication number: 20030074679Abstract: Growth is improved by utilizing growth enhancement potential methodology to administer a nucleic acid sequence, such as GHRH or an analog, to a female animal, preferably through a parenteral route of administration. Piglets born from sows injected with DNA encoding GHRH are larger, and effects are demonstrated in subsequent pregnancies without additional administration(s) of the vector.Type: ApplicationFiled: December 12, 2001Publication date: April 17, 2003Inventors: Robert J. Schwartz, Ruxandra Draghia-Akli, Roy G. Smith, Douglas R. Kern, Robert H. Carpenter